196 related articles for article (PubMed ID: 15789175)
1. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation.
Ray KK; Cannon CP
J Thromb Thrombolysis; 2004 Oct; 18(2):89-101. PubMed ID: 15789175
[TBL] [Abstract][Full Text] [Related]
2. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.
Ray KK; Cannon CP
J Am Coll Cardiol; 2005 Oct; 46(8):1425-33. PubMed ID: 16226165
[TBL] [Abstract][Full Text] [Related]
3. Statin therapy and the management of acute coronary syndromes.
Langer A; Constance C; Fodor JG; Frohlich JJ; Grégoire J; Lau DC; Leiter LA; Mancini GB; Marr D; McPherson R; O'Neill BJ; Rabkin SW
Can J Cardiol; 2003 Jul; 19(8):921-7. PubMed ID: 12876613
[TBL] [Abstract][Full Text] [Related]
4. Early initiation of statin therapy in acute coronary syndromes: a review of the evidence.
Rondina MT; Muhlestein JB
J Interv Cardiol; 2005 Feb; 18(1):55-63. PubMed ID: 15788056
[TBL] [Abstract][Full Text] [Related]
5. The case for intensive statin therapy after acute coronary syndromes.
Schwartz GG; Olsson AG
Am J Cardiol; 2005 Sep; 96(5A):45F-53F. PubMed ID: 16126023
[TBL] [Abstract][Full Text] [Related]
6. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
[TBL] [Abstract][Full Text] [Related]
7. Correlation of systemic inflammation with local inflammatory activity in non-culprit lesions: beneficial effect of statins.
Toutouzas K; Drakopoulou M; Markou V; Karabelas I; Vaina S; Vavuranakis M; Tsiamis E; Tsioufis C; Androulakis A; Stefanadis C
Int J Cardiol; 2007 Jul; 119(3):368-73. PubMed ID: 17258821
[TBL] [Abstract][Full Text] [Related]
8. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Ray KK; Cannon CP; Ganz P
Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
[TBL] [Abstract][Full Text] [Related]
9. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
10. Statin withdrawal: clinical implications and molecular mechanisms.
Cubeddu LX; Seamon MJ
Pharmacotherapy; 2006 Sep; 26(9):1288-96. PubMed ID: 16945051
[TBL] [Abstract][Full Text] [Related]
11. Current questions regarding the use of statins in patients with coronary heart disease.
Rallidis LS; Lekakis J; Kremastinos DT
Int J Cardiol; 2007 Nov; 122(3):188-94. PubMed ID: 17399827
[TBL] [Abstract][Full Text] [Related]
12. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Ito MK; Talbert RL; Tsimikas S
Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy.
Fichtlscherer S; Schmidt-Lucke C; Bojunga S; Rössig L; Heeschen C; Dimmeler S; Zeiher AM
Eur Heart J; 2006 May; 27(10):1182-90. PubMed ID: 16621868
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Settergren M; Böhm F; Rydén L; Pernow J
Eur Heart J; 2008 Jul; 29(14):1753-60. PubMed ID: 18441323
[TBL] [Abstract][Full Text] [Related]
15. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
16. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
17. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
18. Statins and the acute coronary syndrome: 'the early bird catches the worm'.
Nair P; Roguin A
Int J Clin Pract; 2006 Jun; 60(6):716-27. PubMed ID: 16805758
[TBL] [Abstract][Full Text] [Related]
19. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
20. Statins and blood coagulation.
Undas A; Brummel-Ziedins KE; Mann KG
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):287-94. PubMed ID: 15569822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
